GlassScriptPhysician profile
Pooja Banerjee
NPI 1538138011
$21,463.26
in general payments reported to CMS, 2019-2025
25 companies · $5,989 in 2025
The $5,989 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,761 · 2020: $969 · 2021: $895 · 2022: $2,304 · 2023: $1,340 · 2024: $2,206 · 2025: $5,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,449 · Consulting Fee: $3,090 · Travel and Lodging: $1,896 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,449.23 |
| Consulting Fee | $3,090.00 |
| Travel and Lodging | $1,896.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,176.71 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $7,715.24 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,113.61 | 2019-2025 | Rinvoq |
| Amgen INC. | $693.47 | 2019-2025 | Otezla, Uplizna, Tavneos |
| Pfizer INC. | $660.05 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $585.72 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $374.38 | 2019-2023 | Orencia |
| Novartis Pharmaceuticals Corporation | $316.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $307.23 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $241.76 | 2019-2025 | Actemra, Gazyva |
| Aurinia Pharma U.S., INC. | $217.12 | 2022-2025 | Lupkynis |
| Lilly USA, LLC | $175.24 | 2019-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.84 | 2019-2025 | Cyltezo |
| Janssen Scientific Affairs, LLC | $142.35 | 2024 | Tremfya |
| Horizon Therapeutics Plc | $135.12 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $99.92 | 2023-2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $86.80 | 2024 | Strensiq |
| Progentec Diagnostics, INC. | $75.91 | 2023 | |
| Celgene Corporation | $57.67 | 2019 | |
| Organon LLC | $41.11 | 2022-2024 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $35.35 | 2023-2024 | Idacio |
| Sobi, INC | $18.32 | 2019 | |
| Merck Sharp & Dohme LLC | $16.11 | 2020 | |
| Boston Scientific Corporation | $16.00 | 2025 | Enhance Transcarotid Peripheral Access Kit |
| Medexus Pharma, INC. | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.